Every senior officer and three directors at Larimar reported open-market purchases on the same filing day. The dollar amounts are small; the participation is not.
Larimar TherapeuticsInsider buyConviction 81/100
In this brief: 3 sections 2 min read
Hamilton Thomas Edward (Director) — 70,000 @ $2.6726, $187,082.00 · new position
Truitt Joseph (Director) — 3,500 @ $2.7976, $9,791.60 · +127.3%
Breadth and position growth both hit their caps — 30 of 30 for seven distinct insiders, 20 of 20 for growth — and seniority scored the full 15 with the CEO, CFO and COO all buying. Dollar size is what held the total to 81: $382,085.82 spread across seven people scored 15.9 of 35. No penalties: no same-day selling and no rows dropped.
2026-11-12 is the date these Form 4s were filed with the SEC, not the date the trades happened; the purchases here were executed 2026-11-11, 2026-11-12. This is a report of what insiders disclosed and how the score was computed. It is not investment advice.